HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Astria Therapeutics (NASDAQ:ATXS) with an $18 price target.
March 25, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics maintained at Buy with an $18 price target by HC Wainwright & Co.
The reaffirmation of a Buy rating and an $18 price target by a reputable analyst like Joseph Pantginis could positively influence investor sentiment towards ATXS, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100